

# Oncolytic Virus Cancer Therapy- Pipeline Insights, 2019

<https://marketpublishers.com/r/O7836A3509EEN.html>

Date: August 2018

Pages: 200

Price: US\$ 2,000.00 (Single User License)

ID: O7836A3509EEN

## Abstracts

This report can be delivered to the clients within 48 hours

'Oncolytic Virus Cancer Therapy- Pipeline Insights, 2019' report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across Oncolytic Virus Cancer Therapy. A detailed picture of the pipeline landscape is provided with summation of data from multiple sources with complete analysis by development stage, mechanism of action, route of administration and molecule type. This report provides detailed analysis of 65+ products with more than 25 companies involved. Some of the emerging products include Pexa-Vec of Transgene/SillaJen, Telomelsin of Oncolys, and Canerpatrev (TBI-1401) of Takara Bio.

Products covered by Phase

Phase III, Phase II, Phase I

IND

Pre-clinical & Discovery

Inactive

Overview of pipeline development activities for Oncolytic Virus Cancer Therapy

Pipeline analysis of therapeutic drugs include but are not limited to drug description and development activities focusing on clinical and pre-clinical results, designations,

collaborations & licensing deals, grants, technology and patent details.

Therapeutic segmentation of products for Oncolytic Virus Cancer Therapy

The report comprises of comparative pipeline therapeutics assessment by development stage, therapy type, molecule type, and administration route across this mechanism.

## **METHODOLOGY**

Data used in the report are sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight's team of industry experts.

Information and data from the secondary sources have been obtained from various printable and non-printable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

## **SCOPE OF THE REPORT**

Provides an overview of therapeutic pipeline activity for Oncolytic Virus Cancer Therapy across the complete product development cycle including all clinical and non-clinical stages

It comprises of detailed profiles of Oncolytic Virus Cancer Therapy therapeutic products with key coverage of developmental activities including licensing & collaboration deals, patents issued, designations, technologies and chemical information

Therapeutic assessment of the active pipeline products by stage, product type, molecule type, and route of administration

Coverage of dormant and discontinued pipeline projects across Oncolytic Virus Cancer Therapy

## **REASONS TO BUY**

Establish a comprehensive understanding of the current pipeline scenario across Oncolytic Virus Cancer Therapy to formulate effective R&D strategies

Assess challenges and opportunities that influence Oncolytic Virus Cancer Therapy R&D

Gather impartial perspective of strategies of the emerging competitors having potentially lucrative portfolio in this space and create effective counter strategies to gain competitive advantage

Identify the relationship between the products and use it for target finding, drug repurposing, and precision medicine

Devise in licensing and out licensing strategies by identifying prospective partners with progressing projects for Oncolytic Virus Cancer Therapy to enhance and expand business potential and scope

Our extensive domain knowledge on therapy areas support the client in decision-making process regarding their therapeutic portfolio by identifying the reason behind the inactive and discontinued drugs

## Contents

- Executive Summary
- Overview
- Introduction
- History of Oncolytic Virus
- Mechanism of Action
- Criteria of Selection on Oncolytic Virus for Cancer Therapy
- Strategies for Tumor Targeting
- Types of Cancer Treated
- Oncolytic Viruses vs Other Therapies
- Side effects of Oncolytic Viral Therapy
- Limitations of Oncolytic Viral Therapy
- Conclusion and Future Perspectives
- Pipeline Therapeutics (Active Products)
- Pipeline Therapeutics (Inactive Products)
- Comparative Analysis
- Late Stage Products (Phase III)
- Comparative Analysis
- Pexa-Vec: Transgene/SillaJen
- Product Description
- Research and Development
- Product Development Activities
- The list continues
- Mid Stage Products (Phase II)
- Comparative Analysis
- Telomelsin: Oncolys
- Product Description
- Research and Development
- Product Development Activities
- The list continues
- Early Stage Products (Phase I & IND)
- Comparative Analysis
- Pre-clinical and Discovery Stage Products
- Comparative Analysis
- Therapeutic Assessment: Active Products
- Assessment by Stage and Product Type
- Assessment by Route of Administration
- Assessment by Stage and Route of Administration

Assessment by Molecule Type  
Assessment by Stage and Molecule Type  
Inactive Products  
Comparative Analysis

## **APPENDIX**

## List Of Tables

### LIST OF TABLES

#### List of Tables

Table 1: Total Products for Oncolytic Virus Cancer Therapy

Table 2: Late Stage Products (Phase III)

Table 3: Mid Stage Products (Phase II)

Table 4: Early Stage Products (Phase I & IND)

Table 5: Pre-clinical and Discovery Stage Products

Table 6: Assessment by Stage and Product Type

Table 7: Assessment by Route of Administration

Table 8: Assessment by Stage and Route of Administration

Table 9: Assessment by Molecule Type

Table 10: Assessment by Stage and Molecule Type

Table 11: Inactive Products

## List Of Figures

### LIST OF FIGURES

List of Figures

Figure 1: Total Products for Oncolytic Virus Cancer Therapy

Figure 2: Late Stage Products (Phase III)

Figure 3: Mid Stage Products (Phase II)

Figure 4: Early Stage Products (Phase I & IND)

Figure 5: Pre-clinical and Discovery Stage Products

Figure 6: Assessment by Stage and Product Type

Figure 7: Assessment by Route of Administration

Figure 8: Assessment by Stage and Route of Administration

Figure 9: Assessment by Molecule Type

Figure 10: Assessment by Stage and Molecule Type

Figure 11: Inactive Products

### KEY COMPANIES

SillaJen

Oryx

PsiOxus Therapeutics

Daiichi Sankyo

Vyriad

Genelux

Takara Bio

DNATRIX

Merck

Oncolytics Biotech

Oncolys BioPharma

Vrittu Biologics limited

Transgene

VCN Biosciences

CZ Biomed

Cell Genesys

Lokon Pharma

## I would like to order

Product name: Oncolytic Virus Cancer Therapy- Pipeline Insights, 2019

Product link: <https://marketpublishers.com/r/O7836A3509EEN.html>

Price: US\$ 2,000.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/O7836A3509EEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:  
Last name:  
Email:  
Company:  
Address:  
City:  
Zip code:  
Country:  
Tel:  
Fax:  
Your message:

**\*\*All fields are required**

Customer signature \_\_\_\_\_

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970